Over 20 Cleansweep Auctions End Tomorrow 06/25 - Bid Now

FDA rejects imaging agent for Alzheimer's disease detection

by Olga Deshchenko, DOTmed News Reporter | March 18, 2011
The U.S. Food and Drug Administration rejected Amyvid, a molecular imaging agent for the detection of Alzheimer's disease, its makers said Friday.

Amyvid, a PET imaging agent under investigation for the detection of beta-amyloid plaque in living patients' brains, is produced by Eli Lilly and Company's subsidiary Avid Radiopharmaceuticals, Inc.

In its denial of approval for the dye, the FDA focused "on the need to establish a reader training program for market implementation that helps to ensure reader accuracy and consistency of interpretations of existing Amyvid scans," the drug's makers said in a statement.
DOTmed text ad

New Fully Configured 80-slice CT in 2 weeks with Software Upgrades for Life

For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.

In January, an FDA advisory panel asked the company for more evidence on the florbetapir F18 agent. The companies said they've been working on the issues raised by the panel and are continuing to cooperate with the FDA.

"Lilly and Avid have been engaged in an active and ongoing dialogue with the FDA," said Wei-Li Shao, Lilly brand director for the agent. "We remain confident in the data submission package for Amyvid."

You Must Be Logged In To Post A Comment